{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T08:26:13Z","timestamp":1795076773786,"version":"4.10.2"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>\n                    Bloodstream infections (BSIs) adversely affect clinical outcome in children with cancer. Over 1 decade, this retrospective cohort study describes pathogen distribution in BSIs and antimicrobial susceptibility against empirical antibiotics frequently prescribed in children with cancer. The antibiotic efficacy was evaluated through the determination of minimal inhibitory concentrations for piperacillin-tazobactam and meropenem and by disk diffusion for remaining antibiotics. From 2004 to 2013, 398 BSIs occurred in 196 children with cancer (median age: 5.4\u2009y), resulting in 457 bacteria. Overall, 266 (58.2%) were Gram-positive, and 191 (41.8%) were Gram-negative with a significant Gram-positive increase over time (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.032). Coagulase-negative staphylococci (74, 16.2%), viridans group streptococci (67, 14.7%),\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    (52, 11.4%), and\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (39, 8.5%) were the most common pathogens. Susceptibility to piperacillin-tazobactam (95.9%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.419) and meropenem (98.9%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.752) was stable over time, and resistance was observed among viridans group streptococci against piperacillin-tazobactam (18%) and meropenem (7%) and among\n                    <jats:italic toggle=\"yes\">Enterobacterales<\/jats:italic>\n                    against piperacillin-tazobactam (3%). Vancomycin showed 98% Gram-positive activity, gentamicin 82% Gram-negative activity and ampicillin, cefotaxime, and cefuroxime were active in 50%, 72%, and 69% of pathogens, respectively, and BSI-related mortality was 0%. In conclusion, over 1 decade, we report an increase in Gram-positive BSIs, and stable, low-resistance rates against currently recommended empirical antibiotics, piperacillin-tazobactam and meropenem.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000002258","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T17:00:08Z","timestamp":1627318808000},"page":"e160-e167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Bloodstream Infections in Children With Cancer: Pathogen Distribution and Antimicrobial Susceptibility Patterns Over a 10-Year Period"],"prefix":"10.1097","volume":"44","author":[{"given":"Sabine F.","family":"Maarbjerg","sequence":"first","affiliation":[{"name":"Pediatrics and Adolescent Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte V.","family":"Kiefer","sequence":"additional","affiliation":[{"name":"Pediatrics and Adolescent Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte K.","family":"Albertsen","sequence":"additional","affiliation":[{"name":"Pediatrics and Adolescent Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schr\u00f8der","sequence":"additional","affiliation":[{"name":"Pediatrics and Adolescent Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikala","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1086\/522533","article-title":"A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation","volume":"45","author":"Castagnola","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.2005.05736.x","article-title":"Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001","volume":"131","author":"Christensen","year":"2005","journal-title":"Br J Haematol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3324\/haematol.2009.020867","article-title":"Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation","volume":"95","author":"Caselli","year":"2010","journal-title":"Haematologica"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/INF.0b013e31828aebc8","article-title":"Antibiotic-resistant gram-negative bacteremia in pediatric oncology patients\u2014risk factors and outcomes","volume":"32","author":"Haeusler","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2013.12.006","article-title":"Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients","volume":"68","author":"Mikulska","year":"2014","journal-title":"J Infect"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijid.2018.03.022","article-title":"Bloodstream infections in cancer patients. Risk factors associated with mortality","volume":"71","author":"Islas-Munoz","year":"2018","journal-title":"Int J Infect Dis"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3947\/ic.2016.48.3.181","article-title":"Increase in antibiotic-resistant gram-negative bacterial infections in febrile neutropenic children","volume":"48","author":"Lee","year":"2016","journal-title":"Infect Chemother"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J Clin Oncol"},{"key":"R9-20250804","first-page":"2295","article-title":"A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia","volume":"20","author":"Manji","year":"2012","journal-title":"Support Care Cancer"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/INF.0b013e318242590e","article-title":"A meta-analysis of antipseudomonal penicillins and cephalosporins in pediatric patients with fever and neutropenia","volume":"31","author":"Manji","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20250804","first-page":"254","article-title":"Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy","volume":"36","author":"Hung","year":"2003","journal-title":"J Microbiol Immunol Infect"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00431-015-2525-5","article-title":"Bloodstream infection in paediatric cancer centres\u2014leukaemia and relapsed malignancies are independent risk factors","volume":"174","author":"Ammann","year":"2015","journal-title":"Eur J Pediatr"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R14-20250804","first-page":"266","article-title":"Polymicrobial bacteremia in pediatric patients","volume":"138","author":"Frommell","year":"1984","journal-title":"Am J Dis Child"},{"key":"R15-20250804","first-page":"2417","article-title":"Bacteria causing bacteremia in pediatric cancer patients presenting with febrile neutropenia\u2014species distribution and susceptibility patterns","volume":"21","author":"Miedema","year":"2013","journal-title":"Support Care Cancer"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijantimicag.2005.01.020","article-title":"Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols","volume":"25","author":"Greenberg","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/IDR.S70486","article-title":"Bacterial bloodstream infections and antimicrobial susceptibility pattern in pediatric hematology\/oncology patients after anticancer chemotherapy","volume":"7","author":"Al-Mulla","year":"2014","journal-title":"Infect Drug Resist"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/598620","article-title":"Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria","volume":"29","author":"Zinner","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1097\/MPH.0000000000001556","article-title":"Gram-negative bacteremia in children with hematologic malignancies and following hematopoietic stem cell transplantation: epidemiology, resistance, and outcome","volume":"41","author":"Vinker-Shuster","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.7314\/APJCP.2014.15.11.4549","article-title":"Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients","volume":"15","author":"Sezgin","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jmii.2011.01.035","article-title":"Antimicrobial susceptibility of bacteremic isolates from cancer patients with or without neutropenia at a medical center in southern Taiwan","volume":"44","author":"Huang","year":"2011","journal-title":"J Microbiol Immunol Infect"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"e2952","DOI":"10.1097\/MD.0000000000002952","article-title":"Viridans group streptococcal infections in children after chemotherapy or stem cell transplantation: a 10-year review from a tertiary pediatric hospital","volume":"95","author":"Nielsen","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1128\/AAC.02340-14","article-title":"Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy","volume":"58","author":"Sime","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.7314\/APJCP.2015.16.14.5691","article-title":"Increasing antimicrobial resistance monitored in surveillance analysis of blood stream infections in febrile neutropenic pediatric oncology patients","volume":"16","author":"El-Mahallawy","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2217\/fmb.14.144","article-title":"Antibiotic susceptibility of gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia","volume":"10","author":"Castagnola","year":"2015","journal-title":"Future Microbiol"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.13816","article-title":"The challenge of antibiotic resistance in haematology patients","volume":"172","author":"Blennow","year":"2016","journal-title":"Br J Haematol"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/bjc.2016.28","article-title":"Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis","volume":"114","author":"Phillips","year":"2016","journal-title":"Br J Cancer"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1200\/JCO.2015.65.8591","article-title":"Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review of randomized trials","volume":"34","author":"Robinson","year":"2016","journal-title":"J Clin Oncol"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1097\/MPH.0000000000001713","article-title":"Meropenem to children with febrile neutropenia induces monoresistant Pseudomonas aeruginosa","volume":"42","author":"Monster","year":"2020","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:14:25Z","timestamp":1754338465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002258","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"2020-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}